

**Final Director's Interests Notice - Appendix 3Z**

PYC Therapeutics Limited (the 'Company') submits the following Appendix 3Z – Final Director's Interests Notice, in relation to the retirement of Mr Douglas Huey.

This ASX announcement was approved and authorised for release by Rohan Hockings CEO of PYC Therapeutics Limited.

**ENDS** For further information, please contact:

**INVESTORS**  
Rohan Hockings  
CEO  
info@pyctx.com

**About PYC Therapeutics**

*PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

---

Tel: +61 8 6151 0994

pyctx.com

**PYC Therapeutics Limited**

ACN 098 391 961

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b> PYC Therapeutics Limited
<b>ACN</b> 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	DOUGLAS HUEY
<b>Date of last notice</b>	12 February 2020
<b>Date that director ceased to be director</b>	6 November 2020

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
6,666,667 unlisted options exercisable by the payment of \$0.063 on or before 28 February 2023.

+ See chapter 19 for defined terms.

For personal use only

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	
Nil	

### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

---

+ See chapter 19 for defined terms.

For personal use only